Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04187898 | Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | completed | Phase 1 | 59 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT03451162 | Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Aug 5, 2024 | clinicaltrials |
| NCT02061423 | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy(Neoadjuvant) | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04728035 | Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance | completed | Phase 1 | 119 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT01618357 | Pre-Operative Radiation and Veliparib for Breast Cancer | completed | Phase 1 | 19 | Richard ZellarsOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT03149081 | A "Window Trial" on Boswellia for Breast Cancer Primary Tumors | completed | Phase 1 | 46 | Medical University of South CarolinaOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04535323 | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | completed | Phase 1 | 34 | Kathy MillerOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03619681 | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer | completed | Phase 1 | 63 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00424164 | Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer(LAPATAM) | completed | Phase 1 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03308201 | Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer | completed | Phase 1 | 55 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06290466 | Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects | completed | Phase 1 | 18 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02476539 | Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | completed | Phase 1 | 28 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT02527746 | Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | completed | Phase 1 | 18 | EVIVE BiotechnologyINDUSTRY | 0 | Feb 23, 2024 | clinicaltrials |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT03012230 | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
| NCT03471663 | A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer | completed | Phase 1 | 200 | InventisBio Co., LtdINDUSTRY | 2 | Jan 8, 2024 | clinicaltrials |
| NCT04983238 | Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | completed | Phase 1 / Phase 2 | 48 | Byondis B.V.INDUSTRY | 3 | Jan 5, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT03052634 | A Study of RC48-ADC in Subjects With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 112 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04431674 | Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Breast Cancer(USmBRT-B) | completed | Phase 1 | 20 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02754011 | Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative(GEP14-LEECAP) | completed | Phase 1 | 18 | UNICANCEROTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01300962 | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | completed | Phase 1 | 47 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04150731 | 16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer | completed | Phase 1 / Phase 2 | 8 | University of AarhusOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02672475 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | completed | Phase 1 | 29 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03481998 | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 104 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials